{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:57:52Z","timestamp":1782197872637,"version":"3.54.5"},"reference-count":87,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bestpracticeobgyn.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.bpobgyn.2015.01.008","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T05:46:25Z","timestamp":1425447985000},"page":"776-789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular staging of gynecological cancer: What is the future?"],"prefix":"10.1016","volume":"29","author":[{"given":"Pratibha S.","family":"Binder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bpobgyn.2015.01.008_bib1","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2002.02.026","article-title":"Revision of the American Joint Committee on Cancer staging system for breast cancer","volume":"20","author":"Singletary","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2015.01.008_bib2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1245\/ASO.2003.02.013","article-title":"Molecular staging of melanoma: sensitivity, specificity, and the search for clinical significance","volume":"10","author":"McMasters","year":"2003","journal-title":"Annals of Surg Oncol"},{"issue":"15","key":"10.1016\/j.bpobgyn.2015.01.008_bib3","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1200\/JCO.2005.00.695","article-title":"Molecular staging for survival prediction of colorectal cancer patients","volume":"23","author":"Eschrich","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.humpath.2004.02.007","article-title":"Prognostic parameters of endometrial carcinoma","volume":"35","author":"Prat","year":"2004","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2015.01.008_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1525-1438.2007.01067.x","article-title":"Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters","volume":"18","author":"Kapucuoglu","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib7","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1200\/JCO.2006.06.7173","article-title":"Molecular and pathologic aspects of endometrial carcinogenesis","volume":"24","author":"Hecht","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.mpdhp.2009.09.002","article-title":"Molecular genetics of endometrial carcinoma","volume":"15","author":"Catasus","year":"2009","journal-title":"Diag Histopath"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00428-013-1509-y","article-title":"Prognostic biomarkers in endometrial and ovarian cancer","volume":"464","author":"Matias-Guiu","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/path.4056","article-title":"Use of mutation profiles to refine the classification of endometrial carcinomas","volume":"228","author":"McConechy","year":"2012","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"The Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bpobgyn.2015.01.008_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/whe.14.13","article-title":"Update on prognostic markers for endometrial cancer","volume":"10","author":"Binder","year":"2014","journal-title":"Women's Health"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib13","first-page":"4569","article-title":"PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells","volume":"61","author":"Zhu","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib14","first-page":"3005","article-title":"PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics","volume":"4","author":"Risinger","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib15","first-page":"2636","article-title":"PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas","volume":"7","author":"Minaguchi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib16","first-page":"1615","article-title":"Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression","volume":"25","author":"Salvesen","year":"2004","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib17","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br J of Cancer"},{"issue":"3","key":"10.1016\/j.bpobgyn.2015.01.008_bib19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ygyno.2013.08.033","article-title":"HER2\/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1\/2 inhibitor","volume":"131","author":"English","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2015.01.008_bib20","doi-asserted-by":"crossref","first-page":"465.e1","DOI":"10.1016\/j.ajog.2013.07.020","article-title":"Oncogenic PIK3CA gene mutations and HER2\/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1\/2)","volume":"209","author":"English","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib21","doi-asserted-by":"crossref","first-page":"e30801","DOI":"10.1371\/journal.pone.0030801","article-title":"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features","volume":"7","author":"Byron","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib22","doi-asserted-by":"crossref","first-page":"e37431","DOI":"10.1371\/journal.pone.0037431","article-title":"Genotype-dependent efficacy of a dual PI3K\/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas","volume":"7","author":"Shoji","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib23","doi-asserted-by":"crossref","first-page":"18351","DOI":"10.1073\/pnas.0907325106","article-title":"Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer","volume":"106","author":"Sos","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.bpobgyn.2015.01.008_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju245","article-title":"Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma","volume":"106","author":"Liu","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1054\/bjoc.2001.2128","article-title":"Activation and activities of the p53 tumor suppressor protein","volume":"85","author":"Balint","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ygyno.2009.11.018","article-title":"p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review","volume":"116","author":"Lee","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib27","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1525-1438.2005.00159.x","article-title":"Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas","volume":"15","author":"Saffari","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib28","first-page":"177","article-title":"p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis","volume":"150","author":"Tashiro","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib29","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1158\/1078-0432.CCR-07-4837","article-title":"Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma","volume":"14","author":"Jia","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/modpathol.2009.5","article-title":"Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis","volume":"22","author":"Catasus","year":"2009","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/whe.13.4","article-title":"Targeted endometrial cancer therapy as a future prospect","volume":"9","author":"Thanapprapasr","year":"2013","journal-title":"Women's Health"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/sj.bjc.6605805","article-title":"Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer","volume":"103","author":"Mori","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2012.07.127","article-title":"Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer","volume":"127","author":"Leslie","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2015.01.008_bib35","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/IGC.0b013e31826f6806","article-title":"Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells","volume":"22","author":"Byron","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2014.07.083","article-title":"A\u00a0phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"135","author":"Powell","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2015.01.008_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2014.03.153","article-title":"Results of Gynecologic Oncology Group (GOG) 229 K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma","volume":"133","author":"Dizon","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib38","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2015.01.008_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2012.12.022","article-title":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib40","first-page":"388","article-title":"The prognostic importance of steroid receptors in endometrial carcinoma","volume":"72","author":"Palmer","year":"1988","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of fulvestrant in recurrent\/metastatic endometrial carcinoma: a Gynecologic Oncology Group study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2015.01.008_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v15i3.204","article-title":"Adjuvant hormonal therapy for stage I endometrial cancer","volume":"15","author":"Gien","year":"2008","journal-title":"Current Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2015.01.008_bib43","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cncr.29046","article-title":"Polymerase \u025b (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing","volume":"121","author":"Billingsley","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2014.05.006","article-title":"POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium","volume":"134","author":"Meng","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib48","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma","volume":"39","author":"Gilks","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/REP-09-0389","article-title":"Human ovarian cancer stem cells","volume":"140","author":"Bapat","year":"2010","journal-title":"Reproduction"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","article-title":"Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance","volume":"8","author":"Alvero","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s10585-012-9482-4","article-title":"CD44+\/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival","volume":"29","author":"Meng","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib52","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/onc.2012.290","article-title":"C-kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt\/beta-catenin-ATP-binding cassette g2 signaling","volume":"32","author":"Chau","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.yexmp.2011.06.005","article-title":"Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome","volume":"91","author":"Luo","year":"2011","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/onc.2008.374","article-title":"Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells","volume":"28","author":"Baba","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib55","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/modpathol.2011.170","article-title":"CD133 expression associated with poor prognosis in ovarian cancer","volume":"25","author":"Zhang","year":"2012","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2015.01.008_bib56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4252\/wjsc.v6.i4.441","article-title":"Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival?","volume":"6","author":"Haygood","year":"2014","journal-title":"World J of Stem Cells"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib57","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib59","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199611073351901","article-title":"Clinical and pathological features of ovarian Cancer in women with Germ-Line mutations of BRCA1","volume":"335","author":"Rubin","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.bpobgyn.2015.01.008_bib60","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib61","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib62","series-title":"NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: breast and ovarian","author":"National Comprehensive Cancer Network","year":"2010"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib63","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2014.02.039","article-title":"PARP inhibitors in ovarian cancer: current status and future promise","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib64","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J\u00a0Nat Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib65","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T","article-title":"K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases","volume":"79","author":"Cuatrecasas","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib66","first-page":"3","article-title":"Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential","volume":"99","author":"Crispens","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib69","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","article-title":"Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1loss","volume":"22","author":"Clarke","year":"2009","journal-title":"Mod Path"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib70","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc Natl Acac Sci USA"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5511","article-title":"Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer","volume":"32","author":"Hamanishi","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib72","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2014.08.033","article-title":"The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer","volume":"135","author":"Secord","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib73","series-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","author":"Gourley","year":"2014"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/gyno.1999.5387","article-title":"A\u00a0randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study","volume":"73","author":"Sedlis","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib75","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/1097-0142(19951115)76:10+<1978::AID-CNCR2820761313>3.0.CO;2-K","article-title":"Prognostic factors of early stage cervical cancer treated by radical hysterectomy","volume":"76","author":"Sevin","year":"1995","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bpobgyn.2015.01.008_bib76","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3892\/mco.2014.324","article-title":"Candidate biomarkers for cervical cancer treatment: potential for clinical practice (Review)","volume":"2","author":"Miho","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib77","first-page":"721","article-title":"Vascular endothelial growth factor and prognosis of cervical carcinoma","volume":"96","author":"Cheng","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2015.01.008_bib78","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ygyno.2008.11.013","article-title":"Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study","volume":"112","author":"Randall","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib79","first-page":"4693","article-title":"Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer","volume":"60","author":"Birner","year":"2000","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.bpobgyn.2015.01.008_bib80","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00404-013-2803-2","article-title":"Detection of Human Papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis","volume":"288","author":"Barreto","year":"2013","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2015.01.008_bib82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/1471-0528.13071","article-title":"HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis","volume":"122","author":"Rodr\u00edguez-Carunchio","year":"2015","journal-title":"Br J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/gyno.1996.0307","article-title":"Influence of microvessel density and vascular permeability factor\/vascular endothelial growth factor expression on prognosis in vulvar cancer","volume":"63","author":"Obermair","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib84","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jcp.2008.057240","article-title":"A\u00a0review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice","volume":"62","author":"Knopp","year":"2009","journal-title":"J\u00a0Clin Pathol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2015.01.008_bib85","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ygyno.2004.01.049","article-title":"A\u00a0comparative study of MMP-2 in vulvar neoplasms","volume":"93","author":"Bovo","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib86","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/IGC.0000000000000103","article-title":"Study of biomolecular and clinical prognostic factors in patients with cancer of the vulva undergoing surgical treatment","volume":"24","author":"Zanvettor","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2015.01.008_bib87","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.anl.2006.12.002","article-title":"Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma","volume":"34","author":"Yamashita","year":"2007","journal-title":"Auris Nasus Larynx"}],"container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693415000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693415000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T18:06:35Z","timestamp":1747764395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693415000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1521693415000310"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2015.01.008","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular staging of gynecological cancer: What is the future?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2015.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}